... depression relationship by education level and race/ethnicity suggests an important role of social or cultural factors in mediating or moderating the relationship between obesity and mood disorders." Source: Archives of General Psychiatry, 2006 Xagena ...
... that it works not only for routine hemophilia but also for the 30 percent of patients who have developed inhibitory antibodies that make normal replacement treatment impossible," Montgomery concludes. Source: Medical College of Wisconsin, 2006 Xagena ...
... is most likely explained by use of pesticides at home or in gardening. Future studies will need to examine which specific pesticides or classes of pesticides are likely to cause Parkinson's disease. Source: Harvard School of Public Health, 2006 Xagena ...
... likely to remember receiving an X-ray than women who had not been diagnosed with the disease. The second was the lack of data on the specific dose and timing of radiation that was received. Source: American Society of Clinical Oncology, 2006 Xagena ...
... the authors write. " Nighttime blood pressure appears to convey additive risk information about congestive heart failure, but its clinical value remains to be established in future studies." Source: Journal of American Medical Association, 2006 Xagena ...
... spinal cord. " Neurons have completely lost the ability to create new cells so there's no danger of creating a tumor. The only growth they're capable of is regeneration of their axons," he said. Source: Columbia University Medical Center, 2006 Xagena ...
... younger than 40 years seem to have a low to moderate absolute risk of cardiovascular disease", comments Booth. " Age should be taken into account in targeting of risk reduction in people with diabetes, " she concludes. Source: The Lancet, 2006 Xagena ...
... centers. The hope is that netrins could be more effective and may not have to be delivered as a gene therapy, making it available to a much larger group of patients, according to Li. Source: University of Utah Health Sciences Center, 2006 Xagena ...
... which single factors in the CBT regimen produce the best results and to what extent booster sessions at 1 to 2 years after initial treatment may be necessary to maintain improvements. " Source: Journal of American Medical Association, 2006 Xagena ...
... genetic modifiers of steroid androgen metabolism, insulin, and a detailed investigation of the insulin growth factor pathway to explore the underlying mechanisms of action in prostate carcinogenesis," suggest the authors. Source: Cancer, 2006 Xagena ...
... the potential for immune modulation of maternal arthritis, are a result of disease activity changes, or are not causally related cannot be determined from these studies," notes researcher J. Lee Nelson. Source: Arthritis & Rheumatism, 2006 Xagena ...
Indeed, Koning noted that in Sweden some years ago gluten was introduced into baby food, which led to a five-fold increase in celiac disease. The problem disappeared when gluten was removed. Source: American Physiological Society, 2006 Xagena ...
... same issue of Neurology. " Maybe this early decline in episodic memory precedes mild cognitive impairment and should be the target of research efforts in the early detection of Alzheimer's disease." Source: American Academy of Neurology, 2006 Xagena ...
... the stage at diagnosis of melanoma in these populations. We hope that earlier diagnosis of melanoma at a more favorable stage will ultimately improve melanoma survival rates in minority populations." Source: Archives of Dermatology, 2006 Xagena ...
... standardization of both surgical and pathological techniques may improve the selection of patients for chemotherapy, thereby avoiding the unnecessary toxic effects and expense for those cured by surgery alone." Source: Archives of Surgery, 2006 Xagena ...
... to the fetus. Implanting a biological heart valve would eliminate the need for blood thinners, but it would be unlikely to last a lifetime, necessitating another open-chest surgery in the future. Source: American College of Cardiology, 2006 Xagena ...
... for patients with inflammatory breast cancer, further research is necessary to delineate subsets of patients who may benefit from alterations in the approach to improve survival from this aggressive disease." Source: Archives of Surgery, 2006 Xagena ...
... areas of the brain causing uncontrolled movements, loss of intellectual faculties, and emotional disturbances. Currently, there is no treatment to delay or prevent Huntington disease in patients. Source: University of British Columbia, 2006 Xagena ...
... Department of Health has linked the high rates of maternal illness and death in South Africa with the absence of accepted and practical guidance for dealing with women who are pregnant and HIV positive. Source: Journal of Clinical Nursing, 2006 Xagena ...
... are underway to determine the effects of long-term use of PDE-5 inhibitors, and others are warranted, especially in patients who are considered at high risk because of chronic cardiovascular disorders." Source: Cedars-Sinai Medical Center, 2006 Xagena ...
... disease, dementia or multiple system atrophy," she says. " Hopefully, early identification of patients with idiopathic RBD will lead to close monitoring and early treatment of any developing neurological disorders." Source: Mayo Clinic, 2006 Xagena ...
... own system in regulating the immune system and therefore, help to boost the immune system in preventing the destruction of insulin-producing pancreatic cells," says Cohen. Source: American Committee for the Weizmann Institute of Science, 2006 Xagena ...
X-rays will be compared and evaluated to assess whether these supplements affect progression of osteoarthritis. Results of the second part of the study are expected in about a year. Source: University of Utah Health Sciences Center, 2006 Xagena ...
... and fit, but have a family history of type 2 diabetes, this could mean taking antidiabetic medication. Either way, these findings could help clinicians to better manage this growing epidemic." Source: Beth Israel Deaconess Medical Center, 2006 Xagena ...
... long run, if there are any unusual side effects to Nilotinib, and then directly compare it with Imatinib in newly diagnosed chronic myelogenous leukemia patients," Kantarjian says. Source: University of Texas M. D. Anderson Cancer Center, 2006 Xagena ...
... types that they have shown are made by SKPs, including nerve cells, and to ask whether these SKP-derived Schwann cells can function in situations of human nervous system disease, such as spinal cord injury. Source: University of Toronto, 2006 Xagena ...
... at medical centers designated level IV comprehensive epilepsy centers by the National Association of Epilepsy Centers. For those who are not surgical candidates, other treatment options are available, says Cascino. Source: Mayo Clinic, 2006 Xagena ...